心房颤动导管消融复发相关生物标志物的研究进展  

Advances in Biomarkers Associated with Recurrence after Catheter Ablation of Atrial Fibrillation

作　　者：刘旨浩 江洪[1] 余锂镭[1] LIU Zhihao;JIANG Hong;YU Lilei(Department of Cardiology,Renmin Hospital of Wuhan University/Cardiac Autonomic Nervous System Research Center of Wuhan University/Cardiovascular Research Institute,Wuhan University/Hubei Key Laboratory of Cardiology,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院心血管内科武汉大学心脏自主神经研究中心武汉大学心血管病研究所心血管病湖北省重点实验室,武汉430060

出　　处：《医学综述》2023年第12期2372-2377,共6页Medical Recapitulate

基　　金：国家自然科学基金(81871486,81970287)。

摘　　要：心房颤动的发生发展过程涉及多种病理生理机制,其中参与发病机制的某些分子具有预测导管消融预后的潜在作用,如炎症相关标志物、纤维化相关标志物、氧化应激相关标志物和心脏功能标志物等。目前临床迫切需要寻找更精准的能够确定心房颤动患者消融术后复发风险的消融前筛查工具,如生物标志物。因此,识别生物标志物有助于个性化用药或在有创操作、新型靶向药物应用前对心房颤动患者进行风险分层,并预测导管消融术后心房颤动的复发。The occurrence and development of atrial fibrillation involve various pathophysiological mechanisms,among which certain molecules involved in the pathogenesis have potential roles in predicting the prognosis of catheter ablation,such as inflammation related markers,fibrosis related markers,oxidative stress related markers,and cardiac function markers.There is an urgent need to find more accurate pre-ablation screening tools,such as biomarkers,that can determine the risk of recurrence in patients with atrial fibrillation after ablation in clinical practice.Therefore,identifying the biomarkers can help individualize medication or stratify the risk of atrial fibrillation patients before invasive procedures or the application of new targeted drugs,and predict the recurrence of atrial fibrillation after catheter ablation.

关 键 词：心房颤动 导管消融 生物标志物 

分 类 号：R541.7[医药卫生—心血管疾病]